Literature DB >> 16741203

Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications.

Shaila Misri1, Pratibha Reebye, Kristin Kendrick, Diana Carter, Deirdre Ryan, Ruth E Grunau, Tim F Oberlander.   

Abstract

OBJECTIVE: Internalizing behaviors in children between 4 and 5 years of age who had been prenatally exposed to psychotropic medications were investigated. The authors had previously reported the effects of prenatal medication exposure in this same cohort when they were newborns and infants at 3 and 8 months of age.
METHOD: Parental/teacher reports and a clinical measure of mother and child interactions were used to assess levels of internalizing behaviors (e.g., depression, anxiety, withdrawal). Outcomes were compared between children with prenatal selective serotonin reuptake inhibitor (SSRI) exposure (N=22) and nonexposed children of healthy, nondepressed, nonmedicated mothers (N=14). Measures of maternal mood were obtained. Ordered logistic regressions, independent-sample t tests, and univariate ANOVAs were used to compare outcomes between groups. Pearson correlations were used to determine associations between maternal mood and child behaviors.
RESULTS: Levels of internalizing behaviors did not differ significantly between children with prenatal psychotropic medication exposure and those not exposed. However, as symptoms of maternal anxiety and depression increased, so did reported internalizing behaviors in their children.
CONCLUSIONS: Prenatal exposure to psychotropic medications was not associated with increased reports of internalizing behaviors at 4 years of age, whereas impaired maternal mood did have an identified impact on child behavior. Further study of complex associations between maternal psychiatric disorders, prenatal SSRI exposure, and childhood internalizing behaviors is required to understand if the child outcome is affected by the illness, medications, or a combination of both.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16741203     DOI: 10.1176/ajp.2006.163.6.1026

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  53 in total

Review 1.  Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

2.  Pregnancy, depression, antidepressants and breast-feeding.

Authors:  Pierre Blier
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

3.  Mood disorders and their pharmacological treatment during pregnancy: is the future child affected?

Authors:  Catherine Monk; Elizabeth M Fitelson; Elizabeth Werner
Journal:  Pediatr Res       Date:  2011-05       Impact factor: 3.756

4.  Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development.

Authors:  Regina C Casper; Allyson A Gilles; Barry E Fleisher; Joan Baran; Gregory Enns; Laura C Lazzeroni
Journal:  Psychopharmacology (Berl)       Date:  2011-04-16       Impact factor: 4.530

Review 5.  Ethical issues in child psychopharmacology research and practice: emphasis on preschoolers.

Authors:  Lacramioara Spetie; L Eugene Arnold
Journal:  Psychopharmacology (Berl)       Date:  2007-02-06       Impact factor: 4.530

Review 6.  Early pharmacological treatment of autism: a rationale for developmental treatment.

Authors:  Terrence C Bethea; Linmarie Sikich
Journal:  Biol Psychiatry       Date:  2007-02-15       Impact factor: 13.382

Review 7.  A role for the serotonin reuptake transporter in the brain and intestinal features of autism spectrum disorders and developmental antidepressant exposure.

Authors:  Kara Gross Margolis
Journal:  J Chem Neuroanat       Date:  2017-02-14       Impact factor: 3.052

Review 8.  Prenatal antidepressant exposure: clinical and preclinical findings.

Authors:  Chase H Bourke; Zachary N Stowe; Michael J Owens
Journal:  Pharmacol Rev       Date:  2014-02-24       Impact factor: 25.468

9.  Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes.

Authors:  Katherine L Wisner; Dorothy K Y Sit; Barbara H Hanusa; Eydie L Moses-Kolko; Debra L Bogen; Diane F Hunker; James M Perel; Sonya Jones-Ivy; Lisa M Bodnar; Lynn T Singer
Journal:  Am J Psychiatry       Date:  2009-03-16       Impact factor: 18.112

10.  A tale of 2s: optimizing maternal-child health in the context of antenatal maternal depression and antidepressant use.

Authors:  Tim F Oberlander; Katherine L Wisner
Journal:  Can J Psychiatry       Date:  2012-09       Impact factor: 4.356

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.